There is almost universal concern in the biomedical research enterprise about the declining productivity of the system. While there seems to be no shortage of scientific opportunity, there are precious few new products reaching the market, and even fewer genuine breakthroughs. Is innovative science enough these days, or are there management and financial innovations that need to go hand-in-hand? What are some of the novel ways companies are seeking to share risk with other stakeholders, from the government to universities to nonprofit organizations? How are these partnerships affecting industry’s priorities and decision-making?
Jeffrey Brewer, President and CEO, Juvenile Diabetes Research Foundation
Susan Desmond-Hellmann, M.D., MPH , Chancellor, University of California, San Francisco
Margaret A. Hamburg, M.D. , Commissioner, U.S. Food and Drug Administration
John Mendlein, Ph.D., J.D., Executive Chairman, Fate Therapeutics and Chairman, aTyr Pharma
Garry Neil, M.D., Corporate Vice President, Corporate Office of Science and Technology, Johnson & Johnson